C-reactive protein haplotype is associated with high PSA as a marker of metastatic prostate cancer but not with overall cancer risk

British Journal of Cancer

Volumn 100, Issue 12, 2009, Pages 1846-1851

  Eklund, C M ^a   Tammela, T L J ^b   Schleutker, J ^b   Hurme, M ^b  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Association study; CRP gene; Immunology; Inflammation; Prostate cancer

Indexed keywords

C REACTIVE PROTEIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ALLELE; ARTICLE; CANCER RISK; CONTROLLED STUDY; CRP GENE; DISEASE ASSOCIATION; DISEASE MARKER; FINLAND; GENE; GENE FREQUENCY; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS;

ADOLESCENT; ADULT; AGED; BONE NEOPLASMS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 67349161322     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605081     Document Type: Article

References (42)

1. Ames BN, Gold LS, Willett WC (1995) The causes and prevention of cancer. Proc Natl Acad Sci USA 92: 5258-5265
2. Baffoe-Bonnie AB, Smith JR, Stephan DA, Schleutker J, Carpten JD, Kainu T, Gillanders EM, Matikainen M, Teslovich TM, Tammela T, Sood R, Balshem AM, Scarborough SD, Xu J, Isaacs WB, Trent JM, Kallioniemi OP, Bailey-Wilson JE (2005) A major locus for hereditary prostate cancer in Finland: localization by linkage disequilibrium of a haplotype in the HPCX region. Hum Genet 117: 307-316
3. Beer TM, Lalani AS, Lee S, Mori M, Eilers KM, Curd JG, Henner WD, Ryan CW, Venner P, Ruether JD, Chi KN (2008) C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial. Cancer 112(11): 2377-2383
4. Carlson CS, Aldred SF, Lee PK, Tracy RP, Schwartz SM, Rieder M, Liu K, Williams OD, Iribarren C, Lewis EC, Fornage M, Boerwinkle E, Gross M, Jaquish C, Nickerson DA, Myers RM, Siscovick DS, Reiner AP (2005) Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels. Am J Hum Genet 77: 64-77
5. Carpten J, Nupponen N, Isaacs S, Sood R, Robbins C, Xu J, Faruque M, Moses T, Ewing C, Gillanders E, Hu P, Bujnovszky P, Makalowska I, Baffoe-Bonnie A, Faith D, Smith J, Stephan D, Wiley K, Brownstein M, Gildea D, Kelly B, Jenkins R, Hostetter G, Matikainen M, Schleutker J, Klinger K, Connors T, Xiang Y, Wang Z, De Marzo A, Papadopoulos N, Kallioniemi OP, Burk R, Meyers D, Gronberg H, Meltzer P, Silverman R, Bailey-Wilson J, Walsh P, Isaacs W, Trent J (2002) Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet 30: 181-184
6. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420: 860-867
7. Crawford DC, Sanders CL, Qin X, Smith JD, Shephard C, Wong M, Witrak L, Rieder MJ, Nickerson DA (2006) Genetic variation is associated with C-reactive protein levels in the Third National Health and Nutrition Examination Survey. Circulation 114: 2458-2465
8. de Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, Altshuler D (2005) Efficiency and power in genetic association studies. Nat Genet 37: 1217-1223
9. De Marzo AM, Marchi VL, Epstein JI, Nelson WG (1999) Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 155: 1985-1992
10. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG (2007) Inflammation in prostate carcinogenesis. Nat Rev Cancer 7: 256-269
11. de Visser KE, Eichten A, Coussens LM (2006) Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6: 24-37
12. Eklund C, Kivimaki M, Islam MS, Juonala M, Kahonen M, Marniemi J, Lehtimaki T, Viikari J, Raitakari OT, Hurme M (2008) C-reactive protein genetics is associated with carotid artery compliance in men in The Cardiovascular Risk in Young Finns Study. Atherosclerosis 196: 841-848
13. Gould JM, Weiser JN (2001) Expression of C-reactive protein in the human respiratory tract. Infect Immun 69: 1747-1754
14. Haider DG, Leuchten N, Schaller G, Gouya G, Kolodjaschna J, Schmetterer L, Kapiotis S, Wolzt M (2006) C-reactive protein is expressed and secreted by peripheral blood mononuclear cells. Clin Exp Immunol 146: 533-539
15. Heikkila K, Ebrahim S, Lawlor DA (2007) A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health 61: 824-833
16. Heikkila K, Harris R, Lowe G, Rumley A, Yarnell J, Gallacher J, Ben-Shlomo Y, Ebrahim S, Lawlor DA (2008) Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control 20(1): 15-26
17. Hindorff LA, Rice KM, Lange LA, Diehr P, Halder I, Walston J, Kwok P, Ziv E, Nievergelt C, Cummings SR, Newman AB, Tracy RP, Psaty BM, Reiner AP (2008) Common variants in the CRP gene in relation to longevity and cause-specific mortality in older adults: the Cardiovascular Health Study. Atherosclerosis 197: 922-930
18. Lindmark F, Zheng SL, Wiklund F, Balter KA, Sun J, Chang B, Hedelin M, Clark J, Johansson JE, Meyers DA, Adami HO, Isaacs W, Gronberg H, Xu J (2005) Interleukin-1 receptor antagonist haplotype associated with prostate cancer risk. Br J Cancer 93: 493-497
19. Lindmark F, Zheng SL, Wiklund F, Bensen J, Balter KA, Chang B, Hedelin M, Clark J, Stattin P, Meyers DA, Adami HO, Isaacs W, Gronberg H, Xu J (2004) H6D polymorphism in macrophage-inhibitory cytokine-1 gene associated with prostate cancer. J Natl Cancer Inst 96: 1248-1254
20. Lu H, Ouyang W, Huang C (2006) Inflammation, a key event in cancer development. Mol Cancer Res 4: 221-233
21. Miller DT, Zee RY, Suk Danik J, Kozlowski P, Chasman DI, Lazarus R, Cook NR, Ridker PM, Kwiatkowski DJ (2005) Association of common CRP gene variants with CRP levels and cardiovascular events. Ann Hum Genet 69: 623-638
22. Montironi R, Mazzucchelli R, Scarpelli M (2002) Precancerous lesions and conditions of the prostate: from morphological and biological characterization to chemoprevention. Ann NY Acad Sci 963: 169-184
23. Nakashima J, Kikuchi E, Miyajima A, Nakagawa K, Oya M, Ohigashi T, Murai M (2008) Simple stratification of survival using bone scan and serum C-reactive protein in prostate cancer patients with metastases. Urol Int 80: 129-133
24. Nelson WG, De Marzo AM, Isaacs WB (2003) Prostate cancer. N Engl J Med 349: 366-381
25. Oesterling JE (1991) Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145: 907-923
26. Platz EA, De Marzo AM, Erlinger TP, Rifai N, Visvanathan K, Hoffman SC, Helzlsouer KJ (2004) No association between pre-diagnostic plasma C-reactive protein concentration and subsequent prostate cancer. Prostate 59: 393-400
27. Putzi MJ, De Marzo AM (2000) Morphologic transitions between proli-ferative inflammatory atrophy and high-grade prostatic intraepithelial neoplasia. Urology 56: 828-832
28. Rana A, Karamanis K, Lucas MG, Chisholm GD (1992) Identification of metastatic disease by T category, gleason score and serum PSA level in patients with carcinoma of the prostate. Br J Urol 69: 277-281
29. Schleutker J, Matikainen M, Smith J, Koivisto P, Baffoe-Bonnie A, Kainu T, Gillanders E, Sankila R, Pukkala E, Carpten J, Stephan D, Tammela T,
30. Brownstein M, Bailey-Wilson J, Trent J, Kallioniemi OP (2000) A genetic epidemiological study of hereditary prostate cancer (HPC) in Finland: frequent HPCX linkage in families with late-onset disease. Clin Cancer Res 6: 4810-4815
31. Seppala EH, Autio V, Duggal P, Ikonen T, Stenman UH, Auvinen A, Bailey-Wilson JE, Tammela TL, Schleutker J (2007) KLF6 IVS1 - 27G A variant and the risk of prostate cancer in Finland. Eur Urol 52: 1076- 1081
32. Siemes C, Visser LE, Coebergh JW, Splinter TA, Witteman JC, Uitterlinden AG, Hofman A, Pols HA, Stricker BH (2006) C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J Clin Oncol 24: 5216-5222
33. Smith JR, Freije D, Carpten JD, Gronberg H, Xu J, Isaacs SD, Brownstein MJ, Bova GS, Guo H, Bujnovszky P, Nusskern DR, Damber JE, Bergh A, Emanuelsson M, Kallioniemi OP, Walker-Daniels J, Bailey-Wilson JE, Beaty TH, Meyers DA, Walsh PC, Collins FS, Trent JM, Isaacs WB (1996) Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 274: 1371-1374
34. Stein MP, Edberg JC, Kimberly RP, Mangan EK, Bharadwaj D, Mold C, Du Clos TW (2000) C-reactive protein binding to FcgammaRIIa on human monocytes and neutrophils is allele-specific. J Clin Invest 105: 369-376
35. Stephens M, Scheet P (2005) Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am J Hum Genet 76: 449-462
36. Suk Danik J, Chasman DI, Cannon CP, Miller DT, Zee RY, Kozlowski P, Kwiatkowski DJ, Ridker PM (2006) Influence of genetic variation in the C-reactive protein gene on the inflammatory response during and after acute coronary ischemia. Ann Hum Genet 70: 705-716
37. Sun J, Turner A, Xu J, Gronberg H, Isaacs W (2007) Genetic variability in inflammation pathways and prostate cancer risk. Urol Oncol 25: 250-259
38. Szalai AJ (2004) C-reactive protein (CRP) and autoimmune disease: facts and conjectures. Clin Dev Immunol 11: 221-226
39. Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A, Boffetta P (2006) Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol Biomarkers Prev 15: 381-384
40. van Leenders GJ, Gage WR, Hicks JL, van Balken B, Aalders TW, Schalken JA, De Marzo AM (2003) Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy. Am J Pathol 162: 1529-1537
41. Xu J, Zheng SL, Komiya A, Mychaleckyj JC, Isaacs SD, Hu JJ, Sterling D, Lange EM, Hawkins GA, Turner A, Ewing CM, Faith DA, Johnson JR, Suzuki H, Bujnovszky P, Wiley KE, DeMarzo AM, Bova GS, Chang B, Hall MC, McCullough DL, Partin AW, Kassabian VS, Carpten JD, Bailey-Wilson JE, Trent JM, Ohar J, Bleecker ER, Walsh PC, Isaacs WB, Meyers DA (2002) Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet 32: 321-325
42. Zheng SL, Augustsson-Balter K, Chang B, Hedelin M, Li L, Adami HO, Bensen J, Li G, Johnasson JE, Turner AR, Adams TS, Meyers DA, Isaacs WB, Xu J, Gronberg H (2004) Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the Cancer Prostate in Sweden Study. Cancer Res 64: 2918-2922